Skip to main content
SpringerLink
Log in

Epidemiologie

ACE-Hemmer und Lungenkrebsrisiko - eine kontroverse Debatte

  • Journalclub
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Batais M, Almigbal T, Alotaibi K et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(17):e25714. https://doi.org/10.1097/MD.0000000000025714

  2. Nguyen L, Ager EI, Neo J, Christophi C. Regulation of colorectal cancer cell epithelial to mesenchymal transition by the renin angiotensin system. J Gastroenterol Hepatol. 2016;31(10):1773-82

  3. Wong CM, Tsang H, Lai HK et al. Cancer Mortality Risks from Long-term Exposure to Ambient Fine Particle. Cancer Epidemiol Biomarkers Prev. 2016;25(5):839-45

Download references

Author information

Authors and Affiliations

  1. Zentrum für Pneumologie und Thoraxchirurgie, Asklepios Lungenklinik Gauting, Robert-Koch-Allee 2, 82131, Gauting, Deutschland

    Daniel Hamberger Dr. med. univ.

Authors
  1. Daniel Hamberger Dr. med. univ.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Hamberger Dr. med. univ..

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamberger, D. ACE-Hemmer und Lungenkrebsrisiko - eine kontroverse Debatte. Pneumo News 15, 14–15 (2023). https://doi.org/10.1007/s15033-023-3489-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-023-3489-1

Search

Navigation